Scott Koenig, M.D., Ph.D., President and Chief Executive Officer [-] Dr. Koenig has been President and Chief Executive Officer of MacroGenics since September 2001. Prior to joining MacroGenics, he served as Senior Vice President of Research at MedImmune Inc., where he participated in the selection and maturation of the company's product pipeline for 11 years. From 1984 to 1990, he worked in the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health, where he investigated the immune response to retroviruses and studied the pathogenesis of AIDS.

Currently, he is Chairman of the Board of Directors at Applied Genetic Therapy Corporation, a private venture-backed biotechnology company developing genetic therapies using adeno-associated virus vectors. Dr. Koenig is a Board member of BIO, as well as a member of its Emerging Companies Section Governing Body.  Dr. Koenig is also a Board member of the Children's Research Institute at the Children's National Medical Center.

Dr. Koenig received his A.B. and Ph.D. from Cornell University and his M.D. from the University of Texas Health Science Center in Houston, where he was elected to Alpha Omega Alpha. He completed his residency in Internal Medicine at the Hospital of the University of Pennsylvania and is Board certified in Internal Medicine and Allergy and Immunology.

James Karrels, Vice President, Chief Financial Officer [-] Mr. Karrels has over 15 years of experience in finance, including approximately ten years working for or on behalf of life science companies. Prior to joining MacroGenics, he was at Jazz Pharmaceuticals, Inc., most recently serving as Executive Director of Finance, where he was responsible for the company’s financial planning and analysis and investor relations activities. He began his career as an analyst at Merrill Lynch & Co. in 1989 and advanced to the position of Director in the Healthcare Investment Banking Group. During his tenure at Merrill Lynch, he participated in more than 30 sole or lead-managed transactions, representing over $25 billion in aggregate transaction value. His activities included the marketing, structuring and execution of IPOs, equity and convertible debt financings, mergers and acquisitions, spin-offs and other transactions.   He is Co-Chairman of the Steering Committee, Baltimore-Washington Chapter of the Association of Bioscience Financial Officers.

Mr. Karrels holds an M.B.A. from Stanford University and a B.B.A. from the University of Notre Dame.

Kathryn Stein, Ph.D., Senior Vice President, Product Development & Regulatory Affairs [-] Ezio Bonvini, M.D., Senior Vice President, Research [-]

Dr. Bonvini comes to MacroGenics with 24 years of research, regulatory and clinical trial design experience spent at the National Cancer Institute, the National Institutes of Health, and more recently at the Food and Drug Administration (FDA) in the Center for Biologics Evaluation and Research (CBER), which is responsible for regulating therapeutic monoclonal antibodies and other proteins. Dr. Bonvini's research dealt with the molecular mechanism of signal transduction by immune receptors in leukocyte activation. During his tenure at CBER, he held several leadership positions in the Division of Monoclonal Antibodies, most recently as the Acting Deputy Division Director and Chief of the Laboratory of Immunobiology, where he was responsible for supervising the research program and the review of monoclonal antibody products from IND to BLA stages. While at the FDA, Dr. Bonvini received several awards for his scientific and regulatory work. His familiarity with all aspects of the scientific, regulatory, and clinical development process for biologics ensures that MacroGenics incorporates consideration for the development of FDA-compliant product candidates from the earliest stages of preclinical development.

Dr. Bonvini received a Diploma in Science from the Scientific Lyceum in Genoa, Italy, and his M.D., summa cum laude, and Specialty Certification in Clinical Hematology from the University of Genoa, School of Medicine, in Genoa, Italy.

Anastasia Daifotis, M.D., Senior Vice President, Clinical Development[-] Dr. Daifotis joined MacroGenics after a distinguished 16 year career in clinical development and global medical affairs management at Merck & Co.  For the two years prior to joining MacroGenics, Dr. Daifotis served as Vice President, Global Medical Affairs, where she led the organization that provides medical support and information to the franchises, markets, healthcare professionals and patients related to Merck’s products and related disease areas.  From 2006-2007, she served as Vice President and General Manager, Respiratory, Bone, Arthritis and Analgesia.  In this role, she built and led a cross-functional team and had responsibility for Merck’s largest franchise.  From 1993 to 2006, Dr. Daifotis held several roles within Merck’s Clinical Research group, each with increasing responsibility, leading to her position as Vice President, Clinical Research and Therapeutic Area Head for Bone, Endocrine, Immunology and Analgesia.  In her various clinical development roles at Merck, she led or supported the development of several commercialized pharmaceutical products.

Prior to joining Merck, Dr. Daifotis completed her general medical training at Mount Sinai Center and was a Postdoctoral Research Fellow in Endocrinology at the Yale University School of Medicine.  While there, she studied the regulation of parathyroid-hormone-related gene in normal tissue.  She holds an M.D. from Albany Medical College and a B.A. from Princeton University.

Jennie P. Mather, Ph.D., Senior Vice President, Stem Cell Research [-] Dr. Mather has thirty years of experience spanning basic research, drug discovery, and development. After a year as an NIH/INSERM Exchange Scientist in Lyon, France, Dr. Mather joined the faculty of The Rockefeller University. In 1984, she moved to Genentech, Inc. where she was a Staff Scientist in, first, the Process Sciences, and then the Discovery Research divisions of Genentech. During this time, she contributed to the development of 8 marketed recombinant protein products. In 1999, Dr. Mather founded Raven biotechnologies, a company focused on the rapid discovery and development of drug targets and antibody therapeutics using a stem cell based platform. Dr. Mather served as CEO for 6 years, growing Raven to a company with a strong pipeline and a product in Phase I clinical trials for cancer. In 2005, Dr. Mather became president and CSO of Raven, overseeing the strong discovery and development program with 5 pre-clinical product candidates. In 2008, MacroGenics acquired Raven. Dr. Mather is an inventor on more than 40 issued U.S. patents and has authored or edited 5 books and more than 150 publications. In 2002, Dr. Mather was named one of the Top Ten Innovators by Red Herring Magazine, and in 2005 named a Technology Pioneer by the World Economic Forum. 

Dr. Mather obtained her Ph.D., and did postdoctoral work, at the University of California, San Diego, and has a BA from Brandeis University.

Eric Risser, Vice President, Business Development [-] Mr. Risser has 15 years of strategy and transaction experience across both small biotechnology and large pharmaceutical companies. Prior to joining MacroGenics, he served as Senior Director, Business Development at Johnson & Johnson Pharmaceuticals, which he joined in 2003. He was responsible for leading global transactions in the pharmaceuticals area, including company acquisitions, product licenses and research collaborations. His areas of expertise included originating collaboration opportunities, managing multi-disciplinary project teams, structuring and negotiating transactions, and formulating integration and alliance management plans. Before Johnson & Johnson, Mr. Risser started and built a successful consulting practice that provided counsel to emerging life science companies in the United States and Europe. He has also worked as a venture capitalist with BankAmerica Ventures and as an investment banker with Lehman Brothers, where he began his career in their New York and London offices. 

Mr. Risser holds an M.B.A. from Stanford University and a B.A. from Yale University.

Joan Brandt, Ph.D., Vice President, Quality [-] Dr. Brandt has over 15 years of experience in quality management in the biotechnology / biopharmaceutical industry. Prior to joining MacroGenics, she was an independent consultant specializing in quality system implementation and development of regulatory CMC submissions. In 2001, Dr. Brandt joined MedImmune where over the next 6 years she held several leadership positions including Vice President of Corporate QA and Vice President of Corporate QC with responsibility for the QA and QC organizations supporting monoclonal antibody, influenza vaccine, and small molecule commercial manufacturing. Other biopharmaceutical experience includes the VP of Quality Control at Parkedale Pharmaceuticals and nine years with the Baxter Hyland Immuno Division in various quality management roles supporting both the plasma fractionation and biotechnology businesses.

Dr. Brandt received her Ph.D. from The Catholic University of America in synthetic organic chemistry and completed a post doctoral fellowship at the Johns Hopkins Regional Oncology Center.

David A. Carlin, Ph.D., Vice President, Biostatistics & Data Management [-] Dr. Carlin has over 23 years of increasing responsibility in the design and analysis of clinical trials in the pharmaceutical/biotechnology industry. Prior to joining MacroGenics, he spent 11 years at MedImmune, Inc., where he held several leadership positions. Dr. Carlin served as Vice President, Biostatistics and Data Management and Vice President, Clinical Research Design. He was responsible for the creation and management of the biostatistics, data management and statistical programming department, and was instrumental in the development and approval of MedImmune's marketed products. While at MedImmune, Dr. Carlin provided expert strategic advice on clinical trial strategy for both pre-marketed and post-marketed compounds. Before joining MedImmune, Dr. Carlin served as Director, Biostatistics and Data Information Systems, at Otsuka America Pharmaceutical and Director, Clinical Research, at Cetus Corporation. Early in his career, Dr. Carlin held the position of lecturer at Golden Gate University and was a statistician at Warner Lambert/Parke-Davis. He completed a postdoctoral fellowship at the University of North Carolina-Chapel Hill, Department of Biostatistics, where he was a Visiting Scholar supported by the National Heart, Lung and Blood Institute of the NIH. He has authored or co-authored several peer-reviewed publications.

Dr. Carlin obtained his Ph.D. and MS in Experimental Psychology at the Illinois Institute of Technology and his Bachelor of Science degree in Psychology from Drake University.

Lynn Cilinski, Vice President and Controller [-] Ms. Cilinski has over 25 years experience in accounting and financial management with particular expertise in government accounting/auditing practices and procedures. Prior to joining MacroGenics in 2003, Ms. Cilinski was the Corporate Controller for three subsidiaries of Covanta Energy, Inc. (formerly known as Ogden Corporation) a large corporation performing services for both commercial clients and the federal government. Ms. Cilinski was responsible for all financial and administrative management and managed the operation of several divisions focused on all aspects of the accounting/administrative functions and overall operating systems.

Ms. Cilinski has a BS in Accounting.

Syd Johnson, Ph.D., Vice President, Antibody Engineering [-]

Dr. Johnson has 20 years of industrial experience encompassing all aspects of the antibody engineering field. Prior to joining MacroGenics in 2001, he spent eleven years at MedImmune, Inc. where he led the preclinical effort to develop humanized monoclonal antibodies to respiratory syncytial virus (RSV). Dr. Johnson is the inventor of Synagis, MedImmune's anti-RSV product, which is the only licensed monoclonal antibody product for prevention of viral infection. Before that, he worked for six years at Genex Corporation (now a part of Enzon, Inc.) during which time he was instrumental in the development of single chain Fv technology for the production of antibody fragments in E. coli.

Dr. Johnson received his B.S. in Biology from Eckerd College and his Ph.D. in Molecular Biology from Vanderbilt University.

Paul Moore, Ph.D., Vice President, Immunology & Cell Biology[-]

Dr. Moore has over 15 years experience working in the biotechnology industry, coordinating efforts focused on the discovery and development of novel biologic based therapies. He began his biotechnology career at Human Genome Sciences, where he directed genomic-based target discovery programs and the preclinical development of various protein and mAb based therapeutics for the treatment of cancer, metabolic, autoimmune and infectious diseases. Notably these efforts led to the discovery of BLyS as a B-cell survival factor providing the basis for the development of Benlysta as a treatment for lupus. Prior to joining MacroGenics in 2008, Dr. Moore spent three years at Celera where he managed oncology target validation and mAb development efforts including those directed at cancer stem cells.  

Dr. Moore obtained his B.Sc. in Biotechnology from the University of Strathclyde, his Ph.D. in Molecular Biology from the University of Glasgow and completed post-doctoral studies at the Roche Institute of Molecular Biology.

Robert Obst, Vice President, Human Resources & Facilities[-]

Mr. Obst has over 36 years of experience in building and managing the Human Resources and Environmental Health & Safety functions at MedImmune, Inc., W.R. Grace, Inc., SmithKline Beckman Corporation and American Cyanamid-Medical Group. As head of HR and EH&S at MedImmune, Mr. Obst played a significant role in that company's organizational development efforts, including the integration of two acquired companies. Mr. Obst is responsible for HR, EH&S, and Facilities at MacroGenics.

Mr. Obst received a BA in Sociology/Business from SUNY at Albany and his MBA in General Management from Pace University.

Joseph Panigot, J.D., Vice President, Legal Affairs [-] Mr. Panigot has almost 16 years of experience in the biotechnology and research products industries. Prior to joining MacroGenics he served as the Director, Business Development and Legal Affairs at MedImmune, Inc. He was the first in-house counsel at MedImmune and was responsible for establishing and building its legal and patent departments. He was also responsible for strategic corporate development activities. During his employment at MedImmune he directly negotiated or played significant roles in transactions totaling more than $20MM. His professional experience prior to MedImmune includes serving in licensing and related technology transfer roles at the University of Maryland and in product development at Life Technologies, Inc.

Mr. Panigot obtained his B.S. in Biology from George Mason University, his M.S. in Forensic Science at The George Washington University and his J.D. from the University of Baltimore. He is registered to practice before the U.S. Patent and Trademark Office and to practice law in D.C., Maryland and Virginia.

Kristan A. Phillips, Vice President, Regulatory Affairs[-]

Ms. Phillips has 20 years of Regulatory experience covering preclinical and clinical development as well as supporting commercial products.  Prior to joining MacroGenics in 2005, she spent 11 years at MedImmune with increasing responsibilities in Regulatory, most recently leading the Immunology and Infectious Disease group.  This role included developing and implementing regulatory strategies for several investigational products (Phases 1-3); and overseeing clinical, nonclinical, quality, manufacturing and facility IND submissions and BLA supplements. Before MedImmune, she worked as a Regulatory professional at Social and Scientific Systems supporting the Division of AIDS in its clinical development efforts.

Ms. Phillips received her BS in Biology from Carlow College and her MS in Biotechnology from Johns Hopkins University.

Stanford J. Stewart, M.D., Vice President, Clinical Oncology Research [-] Dr. Stewart trained in Medical Oncology at Stanford University, and then served as a member of the faculty of the School of Medicine at Vanderbilt University for more than twelve years. He has more than twelve years of experience in the biotechnology industry, joining Matrix Pharmaceutical, Inc. in 1997 as Associate Medical Director. From 1998 until 2001, he was Clinical Scientist on the Herceptin project at Genentech where he guided post-marketing clinical development including the adjuvant breast cancer program. He moved to ALZA Corporation as Senior Medical Director. From 2001 to 2005, he was employed at Corixa Corporation where he rose from Senior Medical Director to Vice President, Clinical Research. From 2005 to 2008, he served as Vice President, Clinical Research at Raven biotechnologies, inc. and joined MacroGenics following the Raven acquisition.

Dr. Stewart holds a B.A. degree from Rice University, and an M.D. from Baylor College of Medicine. In addition to training in Medical Oncology, he did postdoctoral medical training in Internal Medicine at Case Western Reserve University and postdoctoral scientific training in the laboratory of Dr. Ronald Levy at Stanford University.